Immunotherapy Using a Novel Agonistic Anti-IL-2 Antibody Combined with Epigenetic Modulation Limits Tumor Immune Escape and Controls Tumor Growth
Natalia Arenas-Ramirez(University of Zurich)
Cited by 1
Related Papers
Interleukin-2: Biology, Design and Application
|Trends in Immunology|2015|355